The Supreme Court of India has issued a landmark judgment directing all courts across the country to ensure speedy trial and disposal of intellectual property-related cases. Observing that patent, trademark, and copyright suits often linger for years, the Court emphasized that litigation frequently centers on temporary injunctions rather than substantive resolution. It mandated that hearings in IP matters proceed on a day-to-day basis, with final judgments ordinarily delivered within four months from the date of filing. All courts and tribunals have been instructed to punctually and faithfully implement these directives.
In a significant development concerning pharmaceutical patent law, the Delhi High Court addressed an unprecedented attempt to introduce a drug-patent linkage mechanism in India. Bayer Corporation, instead of pursuing a patent infringement suit, filed a writ petition seeking to prevent Cipla’s marketing approval application for its drug "SORANIB" on the grounds of alleged patent infringement. Bayer argued that under a combined reading of Section 2 of the Drugs and Cosmetics Act and Section 48 of the Indian Patent Act, no marketing approval should be granted for drugs covered by existing patents, effectively proposing a linkage system similar to that in the United States.
The Delhi High Court rejected this argument, holding that no such drug-patent linkage mechanism exists in India. The Court noted that the Drugs and Cosmetics Act and the Patent Act serve distinct objectives, with patent validity and infringement determinations falling exclusively within the Controller of Patents’ jurisdiction. It further emphasized that granting marketing approval for a drug does not constitute patent infringement, which must be established through judicial adjudication. The Court also highlighted potential adverse effects on India’s public health policy if such linkage were imposed. Additionally, the Court dismissed Bayer’s claim that Cipla’s "SORANIB" was a "spurious drug," finding no evidence of deception or imitation.
Turning to trademark law, the Delhi High Court examined a dispute involving two registered trademarks: the plaintiff’s "Clinique" and the defendant’s "CLINIQ." Prior to filing suit, the plaintiff had initiated a cancellation petition against the defendant’s mark before the Registrar of Trade Marks. Under Section 124(1)(ii) of the Trade Marks Act, 1999, suits are typically stayed pending resolution of such petitions. However, Section 124(5) empowers courts to grant interlocutory relief, including interim injunctions.
The Court held that a suit for infringement is maintainable against another registered proprietor of an identical or similar mark. It further ruled that while staying suit proceedings pending cancellation petition outcomes, courts may grant interim injunctions restraining the defendant’s use of the mark if prima facie invalidity of the defendant’s registration is established. Accordingly, the Court granted an interim injunction in favor of the plaintiff until the cancellation petition’s disposal.
On the issue of jurisdiction in trademark infringement involving exports, the Delhi High Court affirmed that the existence of a threat of infringement confers jurisdiction to entertain the suit. The Court reasoned that exporting goods from a country constitutes a sale within that country, amounting to trademark infringement.
This principle was applied in a dispute involving the trademark "MAAZA," a mango fruit drink. The defendant had sold and assigned rights to the plaintiff for India only but later registered the mark in Turkey and began exporting under the same mark. The defendant repudiated the agreement, prompting the plaintiff, The Coca-Cola Company, to seek permanent injunction and damages for infringement and passing off.
The Court found that the defendant’s intention to use the trademark, along with direct or indirect use, sufficed to establish jurisdiction. It granted an interim injunction restraining the defendant from using the "MAAZA" mark both within India and for export markets, recognizing such use as trademark infringement.
These rulings collectively underscore the Indian judiciary’s commitment to expediting IP dispute resolution, clarifying the separation of patent and drug regulatory regimes, and reinforcing protections for registered trademarks, including in cross-border contexts. Practitioners are advised to monitor compliance with the Supreme Court’s directives on speedy trials and to consider these precedents when navigating patent, trademark, and pharmaceutical regulatory intersections in India.
Supreme Court of India Mandates Expedited Resolution of Intellectual Property Cases and Clarifies Drug-Patent Linkage Absence The Supreme Court of India has issued a landmark directive requiring all courts to expedite intellectual property (IP) case trials, aiming for final judgments within four months of suit filing. Concurrently, the Delhi H... Read the full IIPLA article: https://iipla.org/news/supreme-court-of-india-mandates-expedited-resolution-of-intellectual-property-cases-and-clarifies-drug-patent-linkage-absence